Chiesi's $1.9 Billion KalVista Deal Shows What Buyers Will Pay for a Single Approved Asset

On April 29, Italy's privately held Chiesi Group announced a definitive agreement to acquire NASDAQ-listed KalVista Pharmaceuticals for $27.00 per share in cash, valuing the equity at approximately $1.9 billion. The price is a 36 percent premium to KalVista's 30-day volume-weighted average share price as of April 28. The transaction, structured as a tender offer with a back-end merger, is not subject to financing conditions and is expected to close in the third quarter of 2026. For business owners and boards thinking about exit timing, this deal is a useful reference point. Chiesi is paying $1.9 billion for a company whose central asset is one approved drug that generated $49 million in revenue last year.

What Chiesi Is Buying

KalVista's principal asset is EKTERLY (sebetralstat), an oral, on-demand therapy for hereditary angioedema (HAE). The drug was approved by the FDA in July 2025, marking a meaningful clinical advance: HAE is a rare genetic disorder characterized by sudden swelling attacks, and most existing treatments are injectable. An oral on-demand therapy that patients can take at the first sign of symptoms changes the standard of care and the addressable population.

The 2025 revenue of $49 million reflects only six months of commercial activity. The growth slope into 2026 is steep, but unproven at scale, and that is the key valuation question. Chiesi is paying for the launch trajectory, the global expansion runway (approvals outside the US still in process), and the strategic fit with its rare disease portfolio.

How to Value a Single-Asset Company

Single-asset deals look like normal M&A from the outside. Inside the model, they are different. Most acquired companies have a base of installed revenue, customer concentration data, contract renewal patterns, and gross margin profiles that diligence teams can stress-test. A single-asset company with a recently launched product has a much narrower data set. The valuation work converges on a few critical inputs.

Total addressable population. For HAE, the prevalence is documented but estimates of the share of patients on prophylactic versus on-demand therapy vary. Reasonable buyers run multiple penetration scenarios.

Pricing realization and gross-to-net. Specialty rare disease products carry high list prices. Net realization depends on payer mix, rebate strategy, and patient assistance programs. Buyers test the gross-to-net assumption against comparables.

Adoption ramp. A new mechanism faces clinician inertia. Real-world evidence, payer formulary placement, and patient advocacy engagement determine the slope of adoption. Buyers map quarter-by-quarter milestones.

Geographic expansion. Outside the US, EKTERLY's commercialization depends on country approvals, reimbursement decisions, and distribution arrangements. Each jurisdiction is a separate timeline.

Patent and exclusivity runway. A rare disease drug with a finite exclusivity window has a finite revenue tail. Discount rates and terminal multiples reflect that.

Why a Premium Was Available

Chiesi's offer represents a 36 percent premium to a 30-day VWAP. That is a meaningful premium for a public-market biotech in 2026 and reflects two things. First, KalVista's stock had not fully priced in the EKTERLY launch trajectory, partly because rare disease product launches are slow to crystallize in public-market multiples and partly because investors had not yet seen a peer transaction to anchor against. Second, Chiesi is a strategic buyer with a long-duration thesis. As a privately held parent, Chiesi can underwrite a longer payback period than a public competitor managing quarterly EPS expectations.

For sellers, the lesson is that public market valuation is not always a reliable benchmark. A stock that trades through a slow-launch quarter or two can leave significant value on the table. A board that has done thoughtful preparation, including independent fairness analysis and a structured market check, will be in a better position to evaluate a strategic offer at a meaningful premium.

Tender Offer Structure

The transaction is structured as a tender offer with a back-end merger for the same consideration. Tender structures move faster than long-form mergers when the buyer is confident in shareholder support. They also bypass the proxy season timeline and reduce the window for interloper bids.

A clean tender offer requires four things to come together: board approval and recommendation, tendering shareholder support, clearance of regulatory conditions, and acceptance of the offer. The fact that the deal is not subject to financing conditions removes one of the most common sources of close uncertainty. For sellers evaluating offers, the absence of a financing condition is a price input, not a logistical detail.

What This Tells Us About Pharma M&A in 2026

Three signals are worth taking from this transaction. First, strategics with patient capital are willing to pay full prices for assets that fit their portfolio. Privately held strategics, family-controlled companies, and PE-backed platforms all have a structural ability to underwrite longer payback periods than public-market peers. Sellers should make sure their bidder universe includes them.

Second, single-asset rare disease companies remain a high-value, narrow category. The combination of clinical differentiation, addressable patient population, and long exclusivity supports headline multiples that look unusual against generalist comps. Sellers in this category should not benchmark against generalist biotech transactions.

Third, the structure of choice is increasingly cash, not stock. In a market where buyers want certainty of close and sellers want certainty of value, all-cash tender offers without financing conditions check the boxes both sides care about. Stock components remain valuable when tax efficiency or strategic alignment is the priority, but cash is the default.